Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Pharmaceuticals announced that the U.S. FDA has accepted the New Drug Application for investigational plozasiran for the ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...

Arrowhead Pharmaceuticals said Friday that the Food and Drug Administration accepted the company's new drug application for its treatment of familial chylomicronemia syndrome, a severe and rare ...

The voices of tomorrow resonated with hope and inspiration today as elementary students from Dallas, Houston, and Chicago took the stage for the final rounds of Foley & Lardner LLP's Annual MLK Jr.

The global composite decking market size is estimated to grow by USD 3.99 billion from 2025 to 2029, according to Technavio. The market is estimated to grow at a CAGR of 16.6% during the forecast ...

In 2024, there were numerous trials and a few regulatory moves related to advancements in lipid management for the prevention ...

Based on the “compelling” Phase 3 trial data generated from Arrowhead’s plozasiran, an RNA interference therapeutic targeting apolipoprotein C-III in familial chylomicronemia syndrome ...

The analysts pointed out the ongoing regulatory review of Arrowhead's leading program, APOC3 targeting siRNA plozasiran, and potential benefits from the recent FDA approval of a similar drug ...

The analysts highlighted the ongoing regulatory review of Arrowhead's leading program, APOC3 targeting siRNA plozasiran, noting its potential benefits from the recent FDA approval of a similar drug, ...

The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome ...